Enhance early melanoma detection with the DermTech Melanoma Test
>99% probability
that a lesion is not melanoma1,3,5
Informs next steps
for further evaluation and treatment
“There is no question that early detection saves lives, and this tool revolutionizes our ability to find melanoma earlier. ”
— Laura Ferris, MD, PhD
Professor and Director of Clinical Trials at the University of Pittsburgh Department of Dermatology
Hear more from Dr. Ferris
Recommended use of the DermTech Melanoma Test
Indicated for use on melanocytic lesions having one or more ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolving)
Additional considerations for use may include6:
- Difficult-to-biopsy areas
- Cosmetically sensitive areas
- Patients who are not good biopsy candidates
The test is not recommended for lesions:
- Already clinically diagnosed as melanoma
- In areas of psoriasis, eczema, and similar conditions
- On palms, soles, nails, mucous membranes, or hair-covered areas that cannot be trimmed
- Previously biopsied and/or scarred
Negative Predictive Value is the proportion of cases with negative test results that are true negatives
Sensitivity is the test's ability to designate an individual with disease as positive.
Clinically proven. Well studied. Widely used.
Negative Predictive Value is the proportion of cases with negative test results that are true negatives
Sensitivity is the test's ability to designate an individual with disease as positive.
- Used to test more than 175,000+ lesions by 4,300+ clinicians to date9
- Clinically and analytically validated, as supported by 20+ peer-reviewed publications which enrolled an aggregate of over 9,000 patients4,6,a,d
- Included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Cutaneous8,b
Easy to order. Easy to collect. Easy to read.
Adhesive Skin Collection Kits supplied at no cost.c To order, contact us or ask your representative.
Press the DermTech Smart Stickers onto a suspicious lesion, then lift to capture the patient’s skin cells.
Results are returned from the DermTech Gene Lab to your office within 5 business days.
Simple, actionable results. Negative: rules out melanoma with >99% Negative Predictive Value.1,3,5
Positive: informs next steps for further evaluation and treatment.
Download Test Requisition Form
The innovative DermTech Gene Lab is CLIA certified, CAP accredited, and licensed by the New York State Department of Health.
Adopt DermTech into your practice, today.
- The Pigmented Lesion Assay (PLA) detects 2 RNA biomarkers: LINC00518 and PRAME.
- The TERT Add-On Assay detects DNA TERT promoter mutations and is only run following PLA testing when ordered and if sufficient genomic material is available. The TERT Add-On Assay does not yet have
Medicare coverage.
bNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
cDistribution of the Adhesive Skin Collection Kit is included in the reimbursement to DermTech for conducting the DermTech Melanoma Test.
dOf our total 22 peer-reviewed publications, 21 include DermTech Melanoma Test without the add-on test for TERT and one includes DermTech Melanoma Test with the add-on test for TERT.
References: 1. Gerami P, et al. J Am Acad Dermatol. 2017;76(1):114-120. 2. Yao Z, et al. J Drugs Dermatol. 2017;16(10):979-986. 3. Jackson S, et al. SKIN J Cutan Med. 2020;4(2):105-110. 4. Ferris L, et al. Dermatol Online J. 2019;25(5):2. 5. Skelsey M, et al. SKIN J Cutan Med. 2021;5(5):512-523. 6. Brouha B, et al. J Drugs Dermatol. 2020;19(3):257-262. 7. Brouha B, et al. SKIN J Cutan Med. 2021;5(1):13-18. 8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Cutaneous V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed October 31, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. 9. Data on file. DermTech, Inc.